Targets › ABCC8
3 programs from 3 companies in 3 trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Gastroenterology, Oncology, Neurology; next expected readout Dec 2026.
Regulator subunit of pancreatic ATP-sensitive potassium channel (KATP), playing a major role in the regulation of insulin release. In pancreatic cells, it forms KATP channels with KCNJ11; KCNJ11 forms the channel pore while ABCC8 is required for activation and regulation. (UniProt, Q09428)
Open in Phaseline: the race on ABCC8, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Rezolute | RZ358 ABCC8 activator (potassium channel opener) | ABCC8 | Phase 3 | Congenital Hyperinsulinism | Nov 2027 |
| Memorial Sloan Kettering Cancer Center | Glipizide Sulfonylurea receptor 1, Kir6.2 blocker | Ion channels, ABCC8 | Phase 2 | Pancreatic Cancer | Dec 2026 |
| Francis Farhadi | Glyburide Sulfonylurea receptor 1, Kir6.2 blocker | Ion channels, ABCC8 | Phase 1 | Acute Spinal Cord Injury | May 2027 |
Congenital Hyperinsulinism (1) Pancreatic Cancer (1) Acute Spinal Cord Injury (1)
small molecule (3)
Rezolute (1) Memorial Sloan Kettering Cancer Center (1) Francis Farhadi (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.